Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for NBIX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 15.06%
March 31, 2026 24.30%
December 31, 2025 19.08%
September 30, 2025 26.36%
June 30, 2025 15.64%
March 31, 2025 1.38%
December 31, 2024 16.42%
September 30, 2024 20.86%
June 30, 2024 11.01%
March 31, 2024 8.42%
December 31, 2023 28.67%
September 30, 2023 16.66%
June 30, 2023 21.10%
March 31, 2023 -18.22%
December 31, 2022 21.60%
September 30, 2022 17.66%
June 30, 2022 -4.47%
March 31, 2022 4.48%
December 31, 2021 -2.34%
September 30, 2021 7.60%
June 30, 2021 14.64%
March 31, 2021 13.57%
December 31, 2020
September 30, 2020 -22.28%
June 30, 2020 26.32%
Date Value
March 31, 2020 15.77%
December 31, 2019 13.93%
September 30, 2019 24.22%
June 30, 2019 27.96%
March 31, 2019 -73.78%
December 31, 2018 13.75%
September 30, 2018 33.45%
June 30, 2018 -6.10%
March 31, 2018 -58.83%
December 31, 2017 7.29%
September 30, 2017 -18.31%
June 30, 2017 -946.9%
March 31, 2017
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016 -128.4%
December 31, 2015
September 30, 2015
June 30, 2015
March 31, 2015 -6.03%
December 31, 2014
September 30, 2014
June 30, 2014
March 31, 2014

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Amarin Corp. Plc -18.12%
Liquidia Corp. 43.52%
Incyte Corp. 34.98%
Krystal Biotech, Inc. 45.94%
Halozyme Therapeutics, Inc. 47.80%